New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ACT;TEVA;ENDP;COV;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
November 20, 2014
05:14 EDTCOVCovidien achieves CE Mark for Nellcor Bedside SpO2 Patient Monitoring System
Subscribe for More Information
November 19, 2014
10:21 EDTENDPHigh option volume stocks
Subscribe for More Information
08:15 EDTCOVMedtronic reported solid Q2 results, says Bernstein
Bernstein notes that Medtronic's (MDT) sales growth accelerated to 5%, and the firm thinks the company's market share of the ICD market is poised to increase next quarter. Bernstein views Medtronic as "a strong buy" into the close of its acquisition of Covidien (COV). The firm reiterates an Outperform rating on Medtronic.
07:33 EDTENDPEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
06:54 EDTCOVMedtronic reiterated as a top pick at JPMorgan
Subscribe for More Information
November 18, 2014
16:26 EDTACTOn The Fly: Closing Wrap
Subscribe for More Information
13:34 EDTACTActavis rallies after analysts push targets north of $300
Shares of drug maker Actavis (ACT) are climbing after a number of analysts cheered the company's acquisition of Allergan (AGN), and activist investor Bill Ackman said he supported the transaction, according to CNBC. WHAT'S NEW: Piper Jaffray analyst David Amsellem responded to Actavis' acquisition of Allergan by hiking his price target on the name to $338 from $280. The combined company has durable assets, a cost-efficient infrastructure, and the willingness to maintain a strong R&D infrastructure, contended Amsellem. Actavis' price-to-earnings ratio is likely to increase, since it has durable assets, while it his very likely to sustain growth of at least 10%, the analyst added. He kept an Overweight rating on the shares. Also extremely upbeat on Actavis following the deal was UBS analyst Marc Goodman. Actavis provides "the best value in the sector" following the deal, as the transaction should accelerate the company's revenue and profit growth, Goodman believes. That growth, in turn, should propel Actavis' price-to-earnings multiple higher, the analyst predicted. He hiked his price target on Actavis to $333 from $278 and kept a Buy rating on the stock. Meanwhile, Pershing Square's Bill Ackman said that he supported Actavis' takeover of Allergan, CNBC reported this morning. The owner of a large stake in Allergan, Ackman had been trying to get the drug maker to sell itself to Valeant (VRX). The activist investor said today that he would no longer push Allergan to hold a special meeting on December 18, CNBC noted. PRICE ACTION: In mid-afternoon trading, Actavis surged 7.5% to $266.50, while Allergan gained 2% to $214.
12:08 EDTCOVOn The Fly: Midday Wrap
Subscribe for More Information
11:22 EDTTEVATeva patent victory over Warner Chilcott, Roche affirmed
The U.S. Court of Appeals for the Federal Circuit ruled that a district court was correct to grant summary judgment to Teva (TEVA) in a patent dispute with Warner Chilcott and Roche (RHHBY) over patents related to osteoporosis drug risedronate.
10:26 EDTACTAckman to withdraw Allergan special meeting request, CNBC reports
Bill Ackman said he will withdraw his request for an Allergan (AGN) special meeting and that he supports the company's planned transaction with Actavis (ACT), according to CNBC's Scott Wapner. Reference Link
10:08 EDTTEVATeva calls active on renewed takeover chatter
Teva November 57 and 58 calls are active on total call volume of 21K contracts (2K puts) following renewed takeover chatter. November call option implied volatility is at 18, December is at 19; compared to its 26-week average of 24 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:47 EDTTEVARumor: Teva moves up on renewed takeover chatter
Subscribe for More Information
09:08 EDTCOVMedtronic says regulatory processes for Covidien deal 'all on track'
Subscribe for More Information
08:59 EDTACTActavis deal positive, says Sterne Agee
Sterne Agee believes that the friendly nature of Actavis' (ACT) takeover of Allergan (AGN) will enable the combined companies to achieve greater revenue growth. The firm thinks the deal will enable the companies to integrate seamlessly, and it thinks that CEO Brent Saunders' experience at Forest and Bausch & Lomb will help him manage Allergan's leading ophthalmology franchises. Sterne keeps a Buy rating on Actavis.
08:00 EDTTEVATeva launches liquid formulation of TREANDA injection in the U.S.
Subscribe for More Information
07:48 EDTACTValeant not likely to raise bid for Allergan, says Canaccord
Subscribe for More Information
07:41 EDTACTActavis provides best value in pharmaceutical sector, says UBS
UBS believes Actavis (ACT) provides the best value in the pharmaceutical sector following its deal to acquire Allergan (AGN). The firm pointed to the double digit accretion to earnings, synergies, and very attractive current valuation. UBS reiterated its Buy rating on Acatvis and raised its price target to $333 from $278.
07:20 EDTCOVMedtronic confirms commitment to Covidien transaction
Subscribe for More Information
06:40 EDTACTActavis price target raised to $338 from $280 at Piper Jaffray
Subscribe for More Information
06:18 EDTACTActavis price target raised to $310 from $290 at Leerink
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use